secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2024-02-08T23:59:59+00:00
Accession:  0001193125-24-027393
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autolus enters $200M equity deal and strategic CAR-T collaboration with BioNTech
--------------------------------------------------------------------------------

- BioNTech invests $200M in Autolus ADS at $6.00 per share, plus $50M upfront under license agreement.
- Autolus grants BioNTech exclusive license to certain binders; total potential milestones up to $582M.
- BioNTech gets rights to use Autolus' UK manufacturing capacity to accelerate BNT211 into pivotal trials.
- BioNTech receives up to mid-single-digit royalty on obe-cel net sales; Autolus retains full control of obe-cel.
- BioNTech gains option to co-commercialize AUTO1/22 and AUTO6NG and a board nomination right.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000119312524027393/0001193125-24-027393-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000119312524027393/d782679d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-027393

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer